

Article

Knowledge, attitude, and acceptance of COVID-19 vaccines 2 among secondary school pupils in Zambia: implications for future educational and sensitisation programmes 4

Steward Mudenda^{1*}, Moses Mukosha¹, Brian Godman^{2,3,4}, Joseph O. Fadare^{5,6}, Olayinka O. Ogunleye^{7,8}, Johanna C. 6 Meyer^{2,9}, Phumzile Skosana¹⁰, Jacob Chama¹, Victor Daka¹¹, Scott K. Matafwali¹², Billy Chabalenge¹³, Bwalya Angel 7 Witika¹⁴ 8 9 ¹Department of Pharmacy, School of Health Sciences, University of Zambia Lusaka, Zambia. Email: stew-10 ard.mudenda@unza.zm 11 ²Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sci-12 ences University, Pretoria 0204, South Africa; Brian.Godman@smu.ac.za; hannelie.meyer@smu.ac.za 13 ³Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman 346, United Arab Emir-14 ates 15 ⁴Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), 16 University of Strathclyde, Glasgow G4 0RE, UK. Email: brian.godman@strath.ac.uk 17 ⁵Department of Pharmacology and Therapeutics, Ekiti State University College of Medicine, Ado-Ekiti 362103, 18 Nigeria; joseph.fadare@eksu.edu.ng 19 ⁶Department of Medicine, Ekiti State University Teaching Hospital, Ado-Ekiti, Nigeria 20 ⁷Department of Pharmacology, Therapeutics and Toxicology, Lagos State University College of Medicine, 21 Ikeja, Lagos, Nigeria; olayinka.ogunleye@lasucom.edu.ng 22 ⁸Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; olayinka.ogun-23 leye@lasucom.edu.ng 24 ⁹South African Vaccination and Immunisation and Centre, Sefako Makgatho Health Sciences University, Preto-25 ria 0204, South Africa 26 ¹⁰Department of Clinical Pharmacy, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria 27 0208, South Africa; phumzile.skosana@smu.ac.za 28 ¹¹Michael Chilufya Sata School of Medicine, Copperbelt University, Ndola P.O. Box 71191, Zambia;dakavic-29 torm@gmail.com 30 ¹²Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene & 31 Citation: To be added by editorial Tropical Medicine, London, United Kingdom; Scott.Matafwali@lshtm.ac.uk 32 ¹³Department of Medicines Control, Zambia Medicines Regulatory Authority, Lusaka, Zambia; bchaba-33 lenge@vahoo.com 34 Academic Editor: First name Last ¹⁴Department of Pharmaceutical Sciences, School of Pharmacy, Sefako Makgatho Health Sciences University, 35 Pretoria 0208, South Africa; bwalya.witika@smu.ac.za 36 37 Correspondence: steward.mudenda@unza.zm 38 39 (Accepted for publication Vaccines) 40 Abstract: The coronavirus disease 2019 (COVID-19) pandemic resulted in the closure of schools to

41 slow the spread of the virus across populations, and vaccines administered to protect people from 42 severe disease, including school children and adolescents. In Zambia, there is currently little infor-43 mation on the acceptance of COVID-19 vaccines among school-going children and adolescents de-44 spite their inclusion in the vaccination programme. This study assessed the knowledge, attitude, 45 and acceptance of COVID-19 vaccines among secondary school pupils in Lusaka, Zambia. A cross-46 sectional study was conducted from August 2022 to October 2022. Of the 998 participants, 646 47 (64.7%) were female, and 127 (12.7%) would accept to be vaccinated. Those who were willing to be 48 vaccinated had better knowledge (68.5% vs 56.3%) and a positive attitude (79.1% vs 33.7%) com-49 pared to those who were hesitant. Overall, the odds of vaccine acceptance were higher among 50

staff during production.

name

Received: date Accepted: date Published: date

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright:© 2022 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/license s/by/4.0/).

Vaccines2022, 10, x. https://doi.org/10.3390/xxxxx



Vaccines 2022, 10, x FOR PEER REVIEW

56

59

60

pupils who had higher knowledge scores (AOR=11.75, 95% CI: 6.51-21.2), positive attitude scores51(AOR=9.85, 95% CI: 4.35-22.2), and those who knew a friend or relative who had died from COVID-5219 (AOR=3.27, 95% CI: 2.14-5.09). The low vaccine acceptance among pupils is of public health concern, emphasizing the need for heightened sensitisation programmes that promote vaccine acceptance among pupils in Zambia.53

Keywords:Adolescents;Attitude;Children;COVID-19 vaccines;Hesitancy;Knowledge;Pupils;57Secondary Schools;Vaccine acceptance58

1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic appreciably increased morbidity and mortality as well as associated costs [1-7]. Public health measures, including lockdowns, border closures, contact tracing and quarantining measures as well as personal protective equipment were introduced across countries, including among African countries, in an attempt to slow the spread of the severe acute respiratory coronavirus type 2 (SARS-CoV-2) in the absence of effective treatments and vaccines [8-13].

Vaccines were developed as one of the key solutions to prevent severe disease, hos-67 pitalisation, and death due to COVID-19 along with controlling the spread of the disease 68 in the absence of effective treatments [14-21]; however, this could be changing [22-27]. 69 These combined development should help to address the adverse consequences of lock-70 down and social distancing measures, including the closure of clinics which in turn neg-71 atively impacted routine immunisation programmes among children, including those in 72 Africa [28,29]. Alongside this, helping to address the negative impact on education fol-73 lowing school closures and concerns exacerbated by the lack of computers and the costs 74 of internet bundles across Africa [30,31]. These concerns resulted in the development, de-75 ployment and administration of COVID-19 vaccines across countries [15,32-38], although 76 there have been concerns with the vaccines and their uptake in some countries [34,35,39]. 77

Vaccines are critical in addressing vaccine-preventable disease outbreaks caused by microorganisms [38,40-42]. However, the use of vaccines and their success in the immunisation of populations requires that individuals are sensitised to their importance, have good knowledge about them and have confidence in their safety and efficacy [43-46]. This though is not always the case among the general population as well as among healthcare workers (HCWs), some of whom have been hesitant to receive COVID-19 vaccines despite their undoubted effectiveness and limited side effects [46-50].

Currently though, acceptance of COVID-19 vaccines is variable across countries 85 [34,35,39,51-54], with many individuals hesitant due to a lack of awareness of the vaccines 86 and their potential impact, limited knowledge and concerns regarding their safety and 87 effectiveness, negative attitudes towards the vaccines as well as fears of adverse effects 88 [336,46,55-57]. As a result, high hesitancy and low vaccination rates have been reported 89 across countries and continents including Africa [39,48,58-65], exacerbated by the spread-90 ing of misinformation and myths [39,64,66-69]. Besides, the development of mutations 91 among the Alpha, Beta, Gamma, Delta, and Omicron variants has raised further questions 92 about the effectiveness of vaccines long-term and also contributed to hesitancy [70,71]. 93 Consequently, this requires that all vaccine candidates that are being developed take into 94 consideration the evolution of SARS-CoV-2 variants [70, 72]. 95

Among school-going children and adolescents, there is currently limited information 96 available about vaccines, including those for COVID-19 [73,74], which can affect children's knowledge, attitudes, and acceptance of vaccines. Consequently, there is a need to 98 develop strategies that will improve vaccine acceptance among school pupils including 99 for COVID-19, specially tailored to hesitant children [75,76]. Potential strategies include 100 improving secondary school pupils' knowledge about COVID-19 infection as studies have 101 shown poor knowledge among the hesitant groups [77,78]. On the other hand, a study 102 reported a vaccination acceptance rate of over 50% among older pupils, with only 12.9% 103 of surveyed pupils opting out of vaccination [76]. Understanding these issues going for-104 ward is important. We do know that preventive measures associated with the COVID-19 105 pandemic negatively impacted secondary school pupils and educational systems gener-106 ally [77,79,80], affecting nearly 1.6 billion school students globally [81]. Consequently, this 107 needs to be urgently addressed, with effective vaccines part of the strategy to alleviate the 108 need for future lockdown and other measures including new potential treatments 109 [38,82,83]. 110

Zambia, a country in sub-Saharan Africa, reported its first case of COVID-19 on 111 March 18, 2020. Concerns with COVID-19 and its impact in Zambia led to the introduction 112 of preventive measures including the closure of schools as well as the implementation of 113 other control measures [84,85]. However, the morbidity and mortality associated with 114 COVID-19 increased significantly during the second and third waves in Zambia, which is 115 a concern [11,85]. The rollout and administration of COVID-19 vaccines commenced in 116 April 2021in Zambia [39,86]. Since then, vaccine acceptance rates of 33.4% and 66% have 117 been reported across the general population in Zambia [62,86], and 24.5% among univer-118 sity students respectively [63]. In January 2022, the health authorities in Zambia started 119 vaccinating secondary school children and adolescents [39]. However, there is currently a 120 dearth of information regarding the knowledge, attitudes, and acceptance of COVID-19 121 vaccines among children and adolescents attending secondary schools in Zambia. Conse-122 quently, this study aimed to address this deficit by assessing the knowledge, attitudes, 123 and acceptance of COVID-19 vaccines among secondary school pupils in Zambia. Without 124 this baseline information, it would be difficult to design programmes to increase vaccine 125 acceptance and uptake among secondary school pupils where this is an issue, with hesi-126 tancy concerns already reported in East Africa among citizens not educated above sec-127 ondary school levels [87]. 128

2. Materials and Methods

2.1. Study design, setting and population

This cross-sectional study was conducted among secondary school pupils in Lusaka,132Zambia, from August 2022 to October 2022, following the rollout of COVID-19 vaccination133in January 2022, amongst children and adolescents aged from 12 to 17 years [39]. In Zam-134bia, secondary schools educate pupils from Grade 8 to Grade 12.135

Since Lusaka is the capital city of Zambia, it was purposefully selected for this study, 136 assuming that should there be knowledge, attitude, and acceptance deficits amongst pupils attending secondary schools in Lusaka, these are likely to be worse among ruraldwelling populations. All vaccinated pupils (29.2%, n=411) were excluded from this study. 140

> 141 142

129

130

131

2.2. Sampling and sample size consideration

A multi-stage random sampling approach was used in this study. Firstly, we ran-143 domly selected 32 secondary schools from a total of 111 secondary schools in Lusaka city. 144 From each school, 2-4 classes were randomly selected to participate in the research using 145 proportion to school size. From each class, all potential pupils were considered for sam-146 pling using a simple random sampling technique to ensure that each pupil in the class 147 will have the same chance of being selected for the study. Before conducting the study, a 148 representative sample size estimated using Raosoft was software 149 (http://www.raosoft.com/samplesize.html). The sample size was estimated at a 95% con-150 fidence level, with a margin of error of 5%, and a finite population of 10,000 for the locality. 151

Vaccines 2022, 10, x FOR PEER REVIEW

A 10% incomplete, loss, or non-response was taken into consideration. With an assumed 152 moderate design effect of 1.5, a minimum sample size of 814 pupils was estimated. The 153 participants had to be registered in a secondary school in Lusaka, Zambia, during the 154 study to be eligible for the study. 155

2.3. Data Collection Tool

This study used a validated self-administered questionnaire from a similar study consisting of four parts [88]. Part I had five questions on the sociodemographic character-159 istics of participants; Part II had five questions regarding the knowledge of participants 160 concerning the COVID-19 vaccines with yes or no response options; Part III had five ques-161 tions on the attitude of participants towards COVID-19 with yes or no or don't know re-162 sponse options, and Part IV had questions on factors that affect acceptance of COVID-19 163 vaccines among secondary school pupils. Finally, vaccine acceptance was assessed by the 164 question; would you accept to be vaccinated against COVID-19? 165

To check for the simplicity of the questions, we conducted a pilot study among 50 pupils from different secondary schools in Lusaka. These pupils did not form part of the principal study. Each child took approximately 20 to 30 minutes to respond to the ques-168 tionnaire. The questionnaire had a Cronbach's alpha of 0.76 for knowledge and 0.84 for attitude scales, indicating acceptable reliability. 170

The questionnaire was subsequently distributed to all unvaccinated eligible pupils in the selected schools after they provided assent. The consent to participate in the study 172 was given by the pupils' parents and guardians. Data collection was undertaken by two data collectors who were trained by the main author (SM).

2.4. Data management and analysis

3. Results

Stata version 17/BE (Stata Corp., College Station, Texas, USA) was used for the sta-177 tistical analysis. All analyses accounted for the clustering of pupils within schools by us-178 ing robust estimation of standard errors.

Knowledge and attitude scales were scored as follows; for each correct answer, a 180 "yes" for knowledge questions and a positive "yes" for attitude questions were assigned a 181 score of one, while an incorrect "no" for knowledge and a negative "no/don't know" for 182 attitude questions were assigned a score of zero. The knowledge and attitude scores were 183 subsequently calculated as the sum of the total scores from all the questions. 184

Continuous variables (age, knowledge and attitude score) were summarised using 185 means and 95% confidence intervals (95% CI) and whether or not the pupil would accept 186 COVID-19 vaccination. We fitted logistic regression models with robust estimation of 187 standard errors with "COVID-19 vaccine acceptance" as the outcome variable and one of 188 the predictor variables at a time, adjusting for age, to assess for any evidence of an associ-189 ation between the variable and COVID-19 vaccine acceptance. 190

Following this, a multivariable logistic regression model was fitted with the 191 knowledge and attitude scores, age and other variables that were significant in single age-192 adjusted models. Interactions between knowledge and attitude scores and the confound-193 ing variables that remained in the final model were considered one by one. 194

195

196

The study enrolled 998 (95% response rate) unvaccinated pupils, of whom 127(12.7%) 197 would accept the COVID-19 vaccine if it was made available. The largest proportion of 198 those who would accept the vaccine were females (85; 66.9%) in Grade 8 (39; 30.7%) and 199 with a mean age of 15.3 years [95% CI: 15.0-15.6]. 200

4 of 16

156

157 158

166 167

169

171

173 174

175

- 179

The characteristics of the surveyed pupils, their socio-demographics, sources of information about COVID-19, and average total scores of knowledge and attitudes towards the COVID-19 vaccine are provided in Table 1. Overall, pupils who would accept vaccination reported good knowledge and attitude scores compared to those who would refuse vaccination (68.5% vs 56.3%) and (79.1% vs 33.7%), respectively. 205

> 206 207

Table 1. Socio-demographics, knowledge and attitude scores by vaccine acceptance

Variables	Total population (N=998)	COVID-19 va	vaccine acceptors	
		No (n=871); n(%)	Yes (n=127); n(%)	
Sex				
Female	646(64.7)	561(64.4)	85(66.9)	
Male	352(35.3)	310(35.6)	42(33.1)	
Living with				
Guardian	43(4.3)	37(4.3)	6(4.7)	
Parents	955(95.7)	834(95.8)	121(95.3)	
School level				
Grade 8	185(18.5)	146 (16.8)	39(30.7)	
Grade 9	200(20.0)	182(20.9)	18(14.2)	
Grade 10	163(16.3)	145(16.7)	18(14.2)	
Grade 11	252(25.3)	219(25.4)	33(26.0)	
Grade 12	198(19.8)	179(20.6)	19(15.0)	
Source of information				
about COVID-19				
Healthcare workers				
No	651(65.2)	575(66.0)	76(59.8)	
Yes	347(34.8)	296(34.0)	51(40.2)	
Mass media (TV/radio)				
No	469(47.0)	407(46.7)	62(48.8)	
Yes	529(53.0)	464(53.3)	65(51.2)	
Social media				
No	635(63.6)	546(62.7)	89(70.1)	
Yes	363(36.4)	325(37.3)	38(30.0)	
Family/friends				
No	749(75.0)	652(75.0)	97(76.4)	
Yes	249(25.0)	219(25.0)	30(23.6)	
Age				
Mean [95% CI]	15.6 [15.5-15.7]	15.7[15.6-15.8]	15.3 [15.0-15.6]	
Total knowledge score %				
Mean [95% CI]	57.8 [56.1-59.5]	56.3 [54.5-58.0]	68.5 [63.5-73.5]	
Total attitude score %				
Mean [95% CI]	39.4 [37.4-41.5]	33.7 [31.6-35.7]	79.1 [74.6-83.5]	

The pupils' experiences during the COVID-19 pandemic are summarized in Table 2.210The majority (855; 85.7%) of the participants had not suffered from COVID-19 but among211these, 46.8% knew a friend or relative who had previously suffered from COVID-19. A212small proportion of participants (158; 15.8%) reported knowing a relative or friend who213had died of COVID-19, and 558(55.9%) mentioned that preventive measures were not214stressful to follow. A larger proportion (779; 78.1%) were able to practice social distancing215and 710(71.1%) were never in quarantine during the pandemic.216

Table 2. COVID-19 experiences of respondents according to vaccine acceptance	

Experiences/condition	Total population, n(%)	COVID-19 va	ccine acceptors
		No, n(%)	Yes, n(%)
Suffered from COVID-19 before			
I don't know	45(4.5)	41(4.7)	4(3.2)
No	855(85.7)	747(85.8)	108(85.0)
Yes	98(9.82)	83(9.5)	15(11.8)
Friend/relative suffered from COVID-19			
I don't know	60(6.0)	60(6.9)	0
No	471(47.2)	420(48.2)	51(40.2)
Yes	467(46.8)	391(44.9)	76(59.8)
A friend/relative died from COVID-19			
I don't know	107(10.7)	99(11.4)	8(6.3)
No	733(73.5)	644(74.0)	89(70.0)
Yes	158(15.8)	128(14.7)	30(23.6)
Quarantined as a result of COVID-19			
I don't know	95(9.5)	87(10.0)	8(6.3)
No	710(71.1)	624(71.6)	86(67.7)
Yes	193(19.3)	160(18.4)	33(26.0)
Able to practice physical and social distancing			
I don't know	52(5.2)	49(5.6)	3(2.4)
No	167(16.7)	151(17.3)	16(12.6)
Yes	779(78.1)	671(77.0)	108(85.0)
Preventive measures were stressful to follow			
I don't know	85(8.5)	76(8.7)	9(7.1)
No	558(55.9)	481(55.2)	77(60.6)
Yes	355(35.6)	314(36.1)	41(32.3)
Suffer from a chronic condition			
I don't know	52(5.2)	50(5.7)	2(1.6)
No	888(89.0)	776(89.1)	112(88.2)
Yes	58(5.8)	45(5.2)	13(10.2)

228

The logistic regression model that adjusted for age, considering one variable at a 224 time, found that attitude and knowledge scores, knowing a friend/relative who died from 225 COVID-19, being in quarantine due to COVID-19 infection and having a chronic condition 226 were associated with COVID-19 vaccine acceptance (Table 3). 227

Table 3. Association between respondent's knowledge and attitude scores and ac-229ceptance of COVID-19 vaccines, adjusting for potential confounding variables230

Characteristics	OR adjusted for	p-value	Adjusted OR	p-value
	age [95% CI]		[95% CI]	
Knowledge score	5.44 [2.41-12.3]	< 0.001	11.75[6.51-21.2]	0.001
Attitude score	11.19[4.87-24.82]	< 0.001	9.85 [4.35-22.2]	< 0.001
Socio demographics				
Age	0.90 [0.82-1.00]	0.040	0.85[0.71-1.01]	0.072
Sex				
Female	Ref			
Male	0.94 [0.64-1.37]	0.730		
Living with				
Guardian	Ref			
Parents	0.80 [0.33-1.89]	0.604		
School level				
Grade 8	Ref		Ref	
Grade 9	0.38[0.21-0.70]	0.002	0.45[0.22-0.93]	0.031
Grade 10	0.51[0.26-1.00]	0.049	0.60[0.26-1.40]	0.235
Grade 11	0.65 [0.33-1.29]	0.217	0.86[0.36-2.09]	0.743
Grade 12	0.47 [0.21-1.05]	0.067	0.77[0.29-2.07]	0.610
Source of information abou	t COVID-19			
Healthcare workers				
No	Ref			
Yes	1.28 [0.89-1.86]	0.889		
Mass media (TV/radio)				
No	Ref			
Yes	0.91 [0.63-1.31]	0.605		
Social media				
No	Ref			
Yes	0.72 [0.49-1.08]	0.114		
Family/friends				
No	Ref			
Yes	0.86 [0.56-1.34]	0.516		
COVID-19 experiences				
Suffered from COVID-19				
before	Ref			
I don't know	1.47 [0.53-4.10]	0.464		
No	1.84 [0.59-5.78]	0.294		

Vaccines 2022, 10, x FOR PEER REVIEW

8 of 16

Yes				
A friend/relative died				
from COVID-19			Ref	
I don't know	Ref		2.53[0.93-7.34]	0.172
No	1.76 [0.84-3.67]	0.132	3.27[2.14-5.09]	0.013
Yes	2.85 [1.28-6.37]	0.010		
Quarantined as a result of				
COVID-19				
I don't know	Ref		1.42[0.64-3.19]	0.390
No	1.54 [0.74-3.21]	0.252	1.72[0.69-4.25]	0.243
Yes	2.36 [1.07-5.20]	0.033		
Able to practice physical				
and social distancing				
I don't know	Ref		2.44[0.48-12.3]	0.280
No	1.81 [0.52-6.32]	0.352	5.28[0.90-8.50]	0.065
Yes	2.29 [0.87-8.95]	0.084		
Preventive measures are				
stressful to follow				
I don't know	Ref			
No	1.42 [0.69-2.91]	0.337		
Yes	1.14 [0.54-2.41]	0.720		
Suffer from a chronic con-				
dition				
I don't know	Ref			
No	3.73 [0.94-14.84]	0.062		
Yes	7.37 [1.66-32.78]	0.009		

NB: 95% CI-95% confidence interval, OR-odds ratio

231 232

After controlling for the modifying variables that were statistically significant at the 233 5% level in the univariable logistic regression model (age, attitude and knowledge score, 234 knowing a friend/relative who died from COVID-19, being in quarantine due to COVID-235 19 and having a chronic condition), the multivariable logistic regression model showed 236 that independent factors associated with COVID-19 vaccine acceptance were knowledge, 237 attitudes, knowing a friend or relative who died from COVID-19 and being in Grade 9 238 compared to Grade 8. 239

Pupils with higher knowledge scores (AOR=11.75, 95% CI: 6.51-21.2), higher attitude 240 scores (AOR=9.85, 95% CI: 4.35-22.2) and those who knew a friend or relative who died 241 from COVID-19 (AOR=3.27, 95% CI: 2.14-5.09) were more likely to accept a COVID-19 242 vaccine. However, being in Grade 9 compared to Grade 8 (AOR=0.45, 95% CI: 0.22-0.93) 243 was associated with lower odds of accepting the COVID-19 vaccine. 244

4. Discussion

To the best of our knowledge, this is the first study conducted in Zambia to assess 246 the knowledge, attitudes, and acceptance of COVID-19 vaccines among pupils attending 247 secondary schools in Zambia. We found that only 12.7% of surveyed pupils would accept 248

302

to be vaccinated if the vaccine was made available. Non-acceptance of the COVID-19 vac-249 cine was associated with poor knowledge in our study, similar to findings in other coun-250 tries [89,90]. Of interest is that pupils who would accept the COVID-19 vaccine had good 251 knowledge regarding the vaccine compared to those who were hesitant (68.5% vs 56.3%), 252 similar to studies in Canada, China (including Hong Kong), and Sweden [89-92]. In addi-253 tion, in our study, pupils who would accept the COVID-19 vaccine had good attitudes 254 towards the vaccine compared to those who were hesitant (79.1% vs 33.7%), which is en-255 couraging. Alongside this, participants who were in Grade 9 and had higher scores of 256 knowledge and attitudes, and those who knew a friend or relative who died from COVID-257 19, also had higher odds of accepting the vaccine. 258

These findings are consistent with the findings in a systematic review and meta-anal-259 ysis of studies in sub-Saharan Africa where hesitancy was associated with only attending 260 secondary schools and not higher education [87]. However, this was different to studies 261 in Korea among secondary school pupils (69.1% acceptance) with pupils perceiving the 262 vaccines as safe and effective [93], in China (60% acceptance) [89], and England where 263 more than half (50.1%) of those surveyed were willing to be vaccinated and only 12.9% 264 hesitant [76]. These appreciable differences between countries could potentially be due to 265 differences in culture, socio-economic status, and robust vaccine promotion messages. In 266 addition, we have seen appreciable vaccine hesitancy among adults across sub-Saharan 267 Africa [39]. 268

Most of the participants in our study accessed information about COVID-19 vaccines 269 through mass and social media, which can be a concern due to the extent of unverified 270 messages [94]. These findings corroborate reports from others indicating the importance 271 of social and mass media in disseminating information and misinformation concerning 272 vaccines [56,95-98], similar to the situation regarding treatments for patients with COVID-273 19 [94,98,99]. Social media can potentially be used to increase the awareness of individuals 274 regarding COVID-19 vaccines and change their behaviour [98]. This makes social media 275 platforms potentially one of the best and most efficient platforms for addressing vaccine 276 hesitancy by increasing confidence in vaccine safety and effectiveness. However, any 277 youth-friendly COVID-19 messaging should use pertinent platforms and contain appro-278 priate language style to effectively convey key messages regarding the safety and effec-279 tiveness of COVID-19 vaccines [88, 100]. Our findings also indicate that the participants 280 accessed information regarding COVID-19 vaccines from HCWs. This is similar to other 281 findings that have reported HCWs, including school nurses, as one of the main sources of 282 reliable and trusted information concerning COVID-19 vaccines [101,102]. This shows that 283 HCWs must champion the promotion of vaccine acceptance and uptake by providing 284 COVID-19 vaccine education, which has not always been the case [46,49,103-105]. Given 285 this, steps need to be taken to ensure that HCWs do not enhance hesitancy rates given 286 concerns in some studies including among African countries [46-49]. 287

Interestingly in our study, pupils who knew a friend or relative who died from 288 COVID-19 had higher odds of accepting to be vaccinated, which corroborates observa-289 tions from Pakistan and Italy in which adult participants whose friends or family died 290 due to the COVID-19 pandemic had higher odds of accepting the vaccine [106,107]. Such 291 observations can potentially be used in future messaging campaigns to pupils and their 292 parents. However, in other studies, adults who lost a loved one due to the COVID-19 pan-293 demic did not typically see a need to be vaccinated [108]. In contrast, adolescents in one 294 study who strongly believed that COVID-19 is a high-risk infection, and can lead to death, 295 had higher vaccine acceptance rates [93]. 296

The authors are aware of some limitations of this study. Firstly, it was only conducted 297 in Lusaka, which may affect the generalisation of findings to the rest of the secondary 298 schools in the country. Secondly, this was a survey rather than an in-depth discussion 299 with pupils. However, despite this, we believe the findings are robust, providing direction 300 for future nationwide studies. 301

10 of 16

	5. Conclusions	303
	This study found a low COVID-19 vaccine acceptance among secondary school chil-	304
	dren and adolescents in Lusaka City, Zambia. Despite most of the pupils having good scores for knowledge and attitudes, and all of them had heard about COVID-19 vaccines,	305 306
	their low acceptance of the vaccine is of public health concern. The current findings	307
	demonstrate the need for heightened vaccine uptake campaigns in secondary schools	308
	throughout Zambia, which has started to be enacted. We will be following this up in fu-	309
	ture studies.	310 311
	Sunnlamentary Matariala Table S1 Study Questionnaire	
	Supplementary Materials: Table S1 – Study Questionnaire	312
	Author Contributions: Concept and proposal development, SM, MM, BG, JOF, OOO, JCM, PS, JC, VD, BC, BAW; literature review, SM, BG, JOF, OOO, JCM, PS, SKM; data analysis, SM, MM, JCM, PS, JC, BC; interpretation and validation, SM, MM, JC, VD, SKM, BC, BAW; initial draft, SM, BG, JCM, PS; reviewing subsequent drafts, all authors. All authors have read and agreed to the published version of the manuscript.	313314315316317
	Funding: This research received no external funding.	318
	Institutional Review Board Statement: Ethical approval was granted by the University of Zambia Health Sciences Research Ethics Committee (UNZAHSREC). The study was approved under the protocol ID: 202211231183, IORG no: 0009227, IRB no: 00011000. Clearance to collect data was also obtained from the Lusaka District Education Board (DEBs) and the management of the selected schools.	319320321322323
	All participants were informed of the objectives of the study and informed consent was provided	324
	after the pupils took the questionnaire for approval by their parents and guardians.	325
	Informed Consent Statement: As mentioned, all participants were informed of the objectives of the study and informed consent was provided after the pupils took the questionnaire for approval by their parents and guardians.	326 327 328
	Data Availability Statement: Further data is available on reasonable request from the corresponding author.	329 330
	Acknowledgements: We are grateful to the Lusaka District Education Boards (DEBs) for allowing us to conduct this study in secondary schools across Lusaka district in Zambia. We would also like to thank the pupils for accepting to be participants in this study.	331 332 333
	Conflicts of Interest: The authors declare no conflict of interest	334
References		335
1. Ataguba JE. COVID-19 P	andemic, a War to be Won: Understanding its Economic Implications for Africa. Appl Health Econ	336
Health Policy. 2020;18(3):325-8.		337
2. WHO. WHO Coronaviru	s (COVID-19) Dashboard. 2022. Available at URL: <u>https://covid19.who.int/</u>	338
3. Malik P, Patel K, Pinto C,	Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality	339
of life (HRQoL)-A systematic re	view and meta-analysis. J Med Virol. 2022;94(1):253-62.	340
4. de Oliveira Almeida K, N	logueira Alves IG, de Queiroz RS, de Castro MR, Gomes VA, Santos Fontoura FC, et al. A systematic	341
review on physical function, a	activities of daily living and health-related quality of life in COVID-19 survivors. Chronic Illn.	342
2022:17423953221089309.		343
5. Khan M, Adil SF, Alkha	athlan HZ, Tahir MN, Saif S, Khan M, et al. COVID-19: A Global Challenge with Old History,	344
Epidemiology and Progress So I	Far. Molecules. 2020;26(1).	345
6. Richards F, Kodjamanova	P, Chen X, Li N, Atanasov P, Bennetts L, et al. Economic Burden of COVID-19: A Systematic Review.	346
Clinicoecon Outcomes Res. 2022	2;14:293-307.	347

7. Shang W, Wang Y, Yuan J, Guo Z, Liu J, Liu M. Global Excess Mortality during COVID-19 Pandemic: A Systematic Review	348
and Meta-Analysis. Vaccines. 2022;10(10):1702.	349
8. Ogunleye OO, Basu D, Mueller D, Sneddon J, Seaton RA, Yinka-Ogunleye AF, et al. Response to the Novel Corona Virus	350
(COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. Front Pharmacol. 2020;11:1205.	351
9. Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj SB, Ghammam R, et al. Effective public health measures to mitigate the	352
spread of COVID-19: a systematic review. BMC Public Health. 2021;21(1):1015.	353
10. Girum T, Lentiro K, Geremew M, Migora B, Shewamare S, Shimbre MS. Optimal strategies for COVID-19 prevention from	354
global evidence achieved through social distancing, stay at home, travel restriction and lockdown: a systematic review. Arch Public	355
Health. 2021;79(1):150	356
11. Mudenda S, Chileshe M, Mukosha M, Hikaambo CNa, Banda M, Kampamba M, et al. Zambia's Response to the COVID-19	357
Pandemic: Exploring Lessons, Challenges and Implications for Future Policies and Strategies. Pharmacology & Pharmacy.	358
2022;13(1):11-33.	359
12. Talic S, Shah S, Wild H, Gasevic D, Maharaj A, Ademi Z, et al. Effectiveness of public health measures in reducing the incidence	360
of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. Bmj. 2021;375:e068302.	361
13. Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, et al. Quarantine alone or in combination with	362
other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020;9(9):Cd013574.	363
14. Fatima S, Zafar A, Afzal H, Ejaz T, Shamim S, Saleemi S, et al. COVID-19 infection among vaccinated and unvaccinated: Does	364
it make any difference? PLoS One. 2022;17(7):e0270485.	365
15. Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et al. Effectiveness of COVID-19 vaccines	366
in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill. 2021;26(21).	367
16. Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm NM, et al. Vaccines for COVID-19. Clin Exp Immunol.	368
2020;202(2):162-92.	369
17. Korang SK, von Rohden E, Veroniki AA, Ong G, Ngalamika O, Siddiqui F, et al. Vaccines to prevent COVID-19: A living	370
systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. PLoS One.	371
2022;17(1):e0260733.	372
18. WHO. Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness (Revised	373
March 2022). 2022. Available at URL: <u>https://www.who.int/news/item/17-05-2022-statement-for-healthcare-professionals-how-</u>	374
covid-19-vaccines-are-regulated-for-safety-and-effectiveness	375
19. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination	376
SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.	377
Lancet Infect Dis. 2022;22(1):43-55.	378
20. Johnson AG, Amin AB, Ali AR, Hoots B, Cadwell BL, Arora S, et al. COVID-19 Incidence and Death Rates Among	379
Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant	380
Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):132-8.	381
 Dyer O. Covid-19: Unvaccinated face 11 times risk of death from delta variant, CDC data show. Bmj. 2021;374:n2282. 	382
22. Quan BX, Shuai H, Xia AJ, Hou Y, Zeng R, Liu XL, et al. An orally available M(pro) inhibitor is effective against wild-type	383
SARS-CoV-2 and variants including Omicron. Nat Microbiol. 2022;7(5):716-25.	384
23. Ma Y, Yang KS, Geng ZZ, Alugubelli YR, Shaabani N, Vatansever EC, et al. A multi-pronged evaluation of aldehyde-based	385
tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals. Eur J Med Chem. 2022;240:114570.	386
 24. Wang Z, Wang N, Yang L, Song X-q. Bioactive natural products in COVID-19 therapy. Frontiers in Pharmacology. 2022;13. 	387
 24. Wang Z, Wang N, Tang L, Song X-q. Dioactive natural products in COVID-19 therapy. Frontiers in Tharmacology. 2022,13. 25. Schäfer A, Martinez DR, Won JJ, Meganck RM, Moreira FR, Brown AJ, et al. Therapeutic treatment with an oral prodrug of the 	388
remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Sci Transl Med. 2022;14(643):eabm3410.	389
remacorine parentar nucleoside is protective against or no-cov-2 partogenesis in mite, ou rialisi meta. 2022,14(040),eabili0410.	509

26. Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, et al. Discovery of SARS-CoV-2 antiviral drugs through large-	390
scale compound repurposing. Nature. 2020;586(7827):113-9.	391
27. Wang Z, Yang L. In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery. J Med Virol. 2022;94(5):1766-	392
7	393
28. Abbas K, Procter SR, van Zandvoort K, Clark A, Funk S, Mengistu T, et al. Routine childhood immunisation during the COVID-	394
19 pandemic in Africa: a benefit-risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. Lancet Glob Health.	395
2020;8(10):e1264-e72.	396
29. Olorunsaiye CZ, Yusuf KK, Reinhart K, Salihu HM. COVID-19 and Child Vaccination: A Systematic Approach to Closing the	397
Immunization Gap. Int J MCH AIDS. 2020;9(3):381-5.	398
30. Mudenda S, Zulu A, Phiri MN, Ngazimbi M, Mufwambi W, Kasanga M, Banda M. Impact of Coronavirus Disease 2019 (COVID-	399
19) on College and University Students: A Global Health and Education Problem. Aquademia. 2020;4 (2):ep20026	400
31. Etando A, Amu AA, Haque M, Schellack N, Kurdi A, Alrasheedy AA, et al. Challenges and Innovations Brought about by the	401
COVID-19 Pandemic Regarding Medical and Pharmacy Education Especially in Africa and Implications for the Future. Healthcare.	402
2021;9(12	403
32. Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. COVID-19 vaccines: rapid development, implications, challenges and future	404
prospects. Hum Cell. 2021;34(3):711-33.	405
33. Barrett ADT, Titball RW, MacAry PA, Rupp RE, von Messling V, Walker DH, et al. The rapid progress in COVID vaccine	406
development and implementation. NPJ Vaccines. 2022;7(1):20.	407
34. Wang Q, Hu S, Du F, Zang S, Xing Y, Qu Z, et al. Mapping global acceptance and uptake of COVID-19 vaccination: A systematic	408
review and meta-analysis. Communications Medicine. 2022;2(1):113.	409
35. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines.	410
2021;9(2).	411
36. Bono SA, Faria de Moura Villela E, Siau CS, Chen WS, Pengpid S, Hasan MT, et al. Factors Affecting COVID-19 Vaccine	412
Acceptance: An International Survey among Low- and Middle-Income Countries. Vaccines. 2021;9(5).	413
37. Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. Trajectory of long covid symptoms	414
after covid-19 vaccination: community-based cohort study. Bmj. 2022;377:e069676.	415
38. Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The efficacy and effectiveness of the COVID-19	416
vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother.	417
2022;18(1):2027160.	418
39. Ogunleye OO, Godman B, Fadare JO, Mudenda S, Adeoti AO, Yinka-Ogunleye AF, et al. Coronavirus Disease 2019 (COVID-	419
19) Pandemic across Africa: Current Status of Vaccinations and Implications for the Future. Vaccines. 2022;10(9):1553.	420
40. Rodrigues CMC, Plotkin SA. Impact of Vaccines; Health, Economic and Social Perspectives. Front Microbiol. 2020;11:1526.	421
41. Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci.	422
2014;369(1645):20130433.	423
42. Schuchat A. Human Vaccines and Their Importance to Public Health. Procedia in Vaccinology. 2011;5:120-6.	424
43. Singh P, Dhalaria P, Kashyap S, Soni GK, Nandi P, Ghosh S, et al. Strategies to overcome vaccine hesitancy: a systematic review.	425
Syst Rev. 2022;11(1):78.	426
44. Elgendy MO, Abdelrahim MEA. Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy. J Med Virol.	427
2021;93(12):6535-43.	428
45. Haile ZT, Ruhil A, Bates BR, Hall O, Grijalva MJ. Correlates of Covid-19 Vaccine Acceptance among Residents of Ohio: A	429
Cross-sectional Study. BMC Public Health. 2022;22(1):226.	430

46. Adane M, Ademas A, Kloos H. Knowledge, attitudes, and perceptions of COVID-19 vaccine and refusal to receive COVID-19	431
vaccine among healthcare workers in northeastern Ethiopia. BMC Public Health. 2022;22(1):128.	432
47. Ackah M, Ameyaw L, Gazali Salifu M, Afi Asubonteng DP, Osei Yeboah C, Narkotey Annor E, et al. COVID-19 vaccine	433
acceptance among health care workers in Africa: A systematic review and meta-analysis. PLoS One. 2022;17(5):e0268711.	434
48. Kabamba Nzaji M, Kabamba Ngombe L, Ngoie Mwamba G, Banza Ndala DB, Mbidi Miema J, Luhata Lungoyo C, et al.	435
Acceptability of Vaccination Against COVID-19 Among Healthcare Workers in the Democratic Republic of the Congo. Pragmat Obs	436
Res. 2020;11:103-9.	437
49. Amuzie CI, Odini F, Kalu KU, Izuka M, Nwamoh U, Emma-Ukaegbu U, et al. COVID-19 vaccine hesitancy among healthcare	438
workers and its socio-demographic determinants in Abia State, Southeastern Nigeria: a cross-sectional study. Pan Afr Med J.	439
2021;40:10.	440
50. Li M, Luo Y, Watson R, Zheng Y, Ren J, Tang J, et al. Healthcare workers' (HCWs) attitudes and related factors towards COVID-	441
19 vaccination: a rapid systematic review. Postgrad Med J. 2021.	442
51. Jain V, Schwarz L, Lorgelly P. A Rapid Review of COVID-19 Vaccine Prioritization in the U.S.: Alignment between Federal	443
Guidance and State Practice. Int J Environ Res Public Health. 2021;18(7).	444
52. Bayou FD, Amare SN. Acceptance of COVID-19 Vaccine and Its Associated Factors Among Ethiopian Population: A Systematic	445
Review. Patient Prefer Adherence. 2022;16:1093-103.	446
53. Abebe H, Shitu S, Mose A. Understanding of COVID-19 Vaccine Knowledge, Attitude, Acceptance, and Determinates of	447
COVID-19 Vaccine Acceptance Among Adult Population in Ethiopia. Infect Drug Resist. 2021;14:2015-25.	448
54. Wu J, Ma M, Miao Y, Ye B, Li Q, Tarimo CS, et al. COVID-19 Vaccination Acceptance Among Chinese Population and Its	449
Implications for the Pandemic: A National Cross-Sectional Study. Front Public Health. 2022;10:796467.	450
55. Orangi S, Pinchoff J, Mwanga D, Abuya T, Hamaluba M, Warimwe G, et al. Assessing the Level and Determinants of COVID-	451
19 Vaccine Confidence in Kenya. Vaccines (Basel). 2021;9(8).	452
56. Cascini F, Pantovic A, Al-Ajlouni Y, Failla G, Ricciardi W. Attitudes, acceptance and hesitancy among the general population	453
worldwide to receive the COVID-19 vaccines and their contributing factors: A systematic review. EClinicalMedicine. 2021;40:101113.	454
57. Paul E, Steptoe A, Fancourt D. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public	455
health communications. Lancet Reg Health Eur. 2021;1:100012.	456
58. Kanyanda S, Markhof Y, Wollburg P, Zezza A. Acceptance of COVID-19 vaccines in sub-Saharan Africa: evidence from six	457
national phone surveys. BMJ Open. 2021;11(12):e055159.	458
59. Dinga JN, Sinda LK, Titanji VPK. Assessment of Vaccine Hesitancy to a COVID-19 Vaccine in Cameroonian Adults and Its	459
Global Implication. Vaccines. 2021;9(2).	460
60. Cooper S, van Rooyen H, Wiysonge CS. COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-	461
19 vaccines? Expert Rev Vaccines. 2021;20(8):921-33.	462
61. Raja SM, Osman ME, Musa AO, Hussien AA, Yusuf K. COVID-19 vaccine acceptance, hesitancy, and associated factors among	463
medical students in Sudan. PLoS One. 2022;17(4):e0266670.	464
62. Mudenda S, Hikaambo CN, Daka V, Chileshe M, Mfune RL, Kampamba M, et al. Prevalence and factors associated with	465
COVID-19 vaccine acceptance in Zambia: a web-based cross-sectional study. Pan Afr Med J. 2022;41:112.	466
63. Mudenda S, Mukosha M, Hikaambo CN, Meyer JC, Fadare J, Kampamba M et al. Awareness and acceptance of COVID-19	467
vaccines and associated factors among pharmacy students in Zambia. Malawi Medical Journal 2022;34 (3):236-43.	468
64. Al-Kassim Hassan M, Adam Bala A, Jatau AI. Low rate of COVID-19 vaccination in Africa: a cause for concern. Ther Adv	469
Vaccines Immunother. 2022;10:25151355221088159.	470
65. Ajeigbe O, Arage G, Besong M, Chacha W, Desai R, Doegah P, et al. Culturally relevant COVID-19 vaccine acceptance	471
strategies in sub-Saharan Africa. Lancet Glob Health. 2022;10(8):e1090-e1.	472

66. Ackah BBB, Woo M, Stallwood L, Fazal ZA, Okpani A, Ukah UV, et al. COVID-19 vaccine hesitancy in Africa: a scoping review.	473
Glob Health Res Policy. 2022;7(1):21.	474
67. Sallam M, Dababseh D, Eid H, Hasan H, Taim D, Al-Mahzoum K, et al. Low COVID-19 Vaccine Acceptance Is Correlated with	475
Conspiracy Beliefs among University Students in Jordan. Int J Environ Res Public Health. 2021;18(5).	476
68. Wonodi C, Obi-Jeff C, Adewumi F, Keluo-Udeke SC, Gur-Arie R, Krubiner C, et al. Conspiracy theories and misinformation	477
about COVID-19 in Nigeria: Implications for vaccine demand generation communications. Vaccine. 2022;40(13):2114-21.	478
69. Nuwarda RF, Ramzan I, Weekes L, Kayser V. Vaccine Hesitancy: Contemporary Issues and Historical Background. Vaccines.	479
2022;10(10):1595.	480
70. Malik JA, Ahmed S, Mir A, Shinde M, Bender O, Alshammari F, et al. The SARS-CoV-2 mutations versus vaccine effectiveness:	481
New opportunities to new challenges. J Infect Public Health. 2022;15(2):228-40	482
71. Konishi T. Mutations in SARS-CoV-2 are on the increase against the acquired immunity. PLoS One. 2022;17(7):e0271305	483
72. Gong W, Parkkila S, Wu X, Aspatwar A. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future	484
strategies. Int Rev Immunol. 2022:1-22	485
73. Remes P, Selestine V, Changalucha J, Ross DA, Wight D, de Sanjosé S, et al. A qualitative study of HPV vaccine acceptability	486
among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine. 2012;30(36):5363-7.	487
74. Choi SH, Jo YH, Jo KJ, Park SE. Pediatric and Parents' Attitudes Towards COVID-19 Vaccines and Intention to Vaccinate for	488
Children. J Korean Med Sci. 2021;36(31):e227.	489
 75. Cole JW, A MHC, McGuire K, Berman S, Gardner J, Teegala Y. Motivational interviewing and vaccine acceptance in children: 	490
The MOTIVE study. Vaccine. 2022;40(12):1846-54.	491
76. Fazel M, Puntis S, White SR, Townsend A, Mansfield KL, Viner R, et al. Willingness of children and adolescents to have a	492
COVID-19 vaccination: Results of a large whole schools survey in England. EClinicalMedicine. 2021;40:101144.	492
77. Getawa S, Aynalem M, Bayleyegn B, Adane T. Knowledge, attitude and practice towards COVID-19 among secondary school	494
students in Gondar town, Northwest Ethiopia. PLoS One. 2022;17(5):e0268084.	495
78. Handebo S, Adugna A, Kassie A, Shitu K. Determinants of COVID-19-related knowledge and preventive behaviours among	496
students in reopened secondary schools: cross-sectional study. BMJ Open. 2021;11(4):e050189.	497
79. Khan MJ, Ahmed J. Child education in the time of pandemic: Learning loss and dropout. Child Youth Serv Rev. 2021;127:106065.	498 499
80. Omang TA. Assessing the Impact Covid-19 Pandemic on the Educational Development of Secondary School Students. JINAV:	500
Journal of Information and Visualization. 2021.	501
81. United Nations. Policy Brief - Education during COVID-19 and beyond. 2020 Available at URL:	502
https://unsdg.un.org/sites/default/files/2020-08/sg_policy_brief_covid-19_and_education_august_2020.pdf	503
82. Wang K, Wang L, Li M, Xie B, He L, Wang M, et al. Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2	504
Variants: A Systematic Review and Meta-Analysis. Front Med. 2022;9:820544	505
83. Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic	506
review and meta-analysis. BMC Med. 2022;20(1):200	507
84. Simulundu E, Mupeta F, Chanda-Kapata P, Saasa N, Changula K, Muleya W, et al. First COVID-19 case in Zambia -	508
Comparative phylogenomic analyses of SARS-CoV-2 detected in African countries. Int J Infect Dis. 2021;102:455-9.	509
85. Chileshe M, Mulenga D, Mfune RL, Nyirenda TH, Mwanza J, Mukanga B, et al. Increased number of brought-in-dead cases	510
with COVID-19: is it due to poor health-seeking behaviour among the Zambian population? Pan Afr Med J. 2020;37:136.	511
 Carcelen AC, Prosperi C, Mutembo S, Chongwe G, Mwansa FD, Ndubani P, et al. COVID-19 vaccine hesitancy in Zambia: a 	512
glimpse at the possible challenges ahead for COVID-19 vaccination rollout in sub-Saharan Africa. Hum Vaccin Immunother.	512
2022;18(1):1-6.	514

87. Alemayehu A, Demissie A, Yusuf M, Gemechu Lencha A, Oljira L. Covid-19 Vaccine Acceptance and Determinant Factors	515
among General Public in East Africa: A Systematic Review and Meta-Analysis. Health Serv Res Manag Epidemiol.	516
2022;9:23333928221106269.	517
88. Aklil MB, Temesgan WZ. Knowledge and Attitude towards COVID-19 Vaccination and Associated Factors among College	518
Students in Northwest Ethiopia,2021. Health Serv Res Manag Epidemiol. 2022;9:23333928221098903.	519
89. Rehati P, Amaerjiang N, Yang L, Xiao H, Li M, Zunong J, et al. COVID-19 Vaccine Hesitancy among Adolescents: Cross-	520
Sectional School Survey in Four Chinese Cities Prior to Vaccine Availability. Vaccines (Basel). 2022;10(3).	521
90. Nilsson S, Mattson J, Berghammer M, Brorsson AL, Forsner M, Jenholt Nolbris M, et al. To be or not to be vaccinated against	522
COVID-19 - The adolescents' perspective - A mixed-methods study in Sweden. Vaccine X. 2021;9:100117.	523
91. Afifi TO, Salmon S, Taillieu T, Stewart-Tufescu A, Fortier J, Driedger SM. Older adolescents and young adults willingness to	524
receive the COVID-19 vaccine: Implications for informing public health strategies. Vaccine. 2021;39(26):3473-9.	525
92. Wong WHS, Leung D, Chua GT, Duque JSR, Peare S, So HK, et al. Adolescents' attitudes to the COVID-19 vaccination. Vaccine.	526
2022;40(7):967-9.	527
93. Lee H, Choe YJ, Kim S, Cho HK, Choi EH, Lee J, et al. Attitude and Acceptance of COVID-19 Vaccine in Parents and	528
Adolescents: A Nationwide Survey. J Adolesc Health. 2022;71(2):164-71.	529
94. Schellack N, Strydom M, Pepper MS, Herd CL, Hendricks CL, Bronkhorst E, et al. Social Media and COVID-19; Perceptions	530
and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics. Antibiotics. 2022;11(4):445.	531
95. Wawrzuta D, Klejdysz J, Jaworski M, Gotlib J, Panczyk M. Attitudes toward COVID-19 Vaccination on Social Media: A Cross-	532
Platform Analysis. Vaccines (Basel). 2022;10(8).	533
96. Ahmed S, Rasul ME, Cho J. Social Media News Use Induces COVID-19 Vaccine Hesitancy Through Skepticism Regarding Its	534
Efficacy: A Longitudinal Study From the United States. Frontiers in Psychology. 2022;13.	535
97. Hernandez RG, Hagen L, Walker K, O'Leary H, Lengacher C. The COVID-19 vaccine social media infodemic: healthcare	536
providers' missed dose in addressing misinformation and vaccine hesitancy. Hum Vaccin Immunother. 2021;17(9):2962-4.	537
98. Al-Dmour H, Masa'deh Re, Salman A, Abuhashesh M, Al-Dmour R. Influence of Social Media Platforms on Public Health	538
Protection Against the COVID-19 Pandemic via the Mediating Effects of Public Health Awareness and Behavioral Changes:	539
Integrated Model. J Med Internet Res. 2020;22(8):e19996-e.	540
99. González-Padilla DA, Tortolero-Blanco L. Social media influence in the COVID-19 Pandemic. Int Braz J Urol.	541
2020;46(suppl.1):120-4.	542
100. Scherer AM, Gedlinske AM, Parker AM, Gidengil CA, Askelson NM, Petersen CA, et al. Acceptability of Adolescent COVID-19	543
Vaccination Among Adolescents and Parents of Adolescents - United States, April 15-23, 2021. MMWR Morb Mortal Wkly Rep.	544
2021;70(28):997-1003	545
101. Saleh ASA, Mahmoodi AH, Alradadi AHA, Al-Ansari MM, Majrashi AMH, Mohammed KE et al. Assessment of Perception of	546
Covid-19 Infection and Vaccination among Health Care Workers in Makkah Al-Mokarramah, Saudi Arabia. Annals of the Roma-	547
nian Society for Cell Biology. 2022; 26(01): 3103–3120	548
102. Park K, Cartmill R, Johnson-Gordon B, Landes M, Malik K, Sinnott J, et al. Preparing for a School-Located COVID-19	549
Vaccination Clinic. NASN Sch Nurse. 2021;36(3):156-63(14)	550
103. İkiışık H, Sezerol MA, Taşçı Y, Maral I. COVID-19 vaccine hesitancy and related factors among primary healthcare workers in	551
a district of Istanbul: a cross-sectional study from Turkey. Fam Med Community Health. 2022;10(2)	552
104. Yendewa SA, Ghazzawi M, James PB, Smith M, Massaquoi SP, Babawo LS, et al. COVID-19 Vaccine Hesitancy among	553
Healthcare Workers and Trainees in Freetown, Sierra Leone: A Cross-Sectional Study. Vaccines. 2022;10(5)	554
105. Blake H, Fecowycz A, Starbuck H, Jones W. COVID-19 Vaccine Education (CoVE) for Health and Care Workers to Facilitate	555
Global Promotion of the COVID-19 Vaccines. Int J Environ Res Public Health. 2022;19(2)	556

106. Tahir MJ, Saqlain M, Tariq W, Waheed S, Tan SHS, Nasir SI, et al. Population preferences and attitudes towards COVID-19	557
vaccination: a cross-sectional study from Pakistan. BMC Public Health. 2021;21(1):1759.	558
107. Contoli B, Possenti V, Minardi V, Binkin NJ, Ramigni M, Carrozzi G, et al. What Is the Willingness to Receive Vaccination	559
Against COVID-19 Among the Elderly in Italy? Data From the PASSI d'Argento Surveillance System. Front Public Health.	560
2021;9:736976.	561
108. Tibbels NJ, Dosso A, Fordham C, Benie W, Brou JA, Kamara D, et al. "On the last day of the last month, I will go": A qualitative	562
exploration of COVID-19 vaccine confidence among Ivoirian adults. Vaccine. 2022;40(13):2028-35.	563
	564
	565